<DOC>
	<DOCNO>NCT00444782</DOCNO>
	<brief_summary>The purpose study investigate efficacy GV1001 locally advance metastatic HCC . Also safety GV1001 immunogenicity evaluate .</brief_summary>
	<brief_title>A Phase II , Open-Label Trial Evaluating GV1001 Advanced Hepatocellular Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Hepatocellular carcinoma diagnosis fulfil one follow criterion ( per American Association Study Liver Diseases [ AASLD ] guideline , see Appendix 5 ) : 1 . Nodule cirrhotic noncirrhotic liver biopsy show HCC ; 2 . Nodule cirrhotic liver biopsy perform : Nodules 12 cm cirrhotic liver typical coincidal vascular pattern HCC ( i.e . hypervascular washout portal/venous phase ) two dynamic study : either CT scan , contrast ultrasound MRI contrast . Nodule large 2 cm cirrhotic liver typical vascular pattern HCC dynamic imaging technique . Please note : HCC noncirrhotic liver diagnose biopsy show HCC . Measurable disease accord modify RECIST ( see Appendix 7 ) . At least one treatmentnaïve target lesion ( treatmentnaïve define treat local therapy , surgery , radiation therapy , hepatic arterial embolisation , chemoembolisation , radiofrequency ablation cryoablation ) . Barcelona Clinic Liver Cancer ( BCLC ) stage A , B C ( see Appendix 6 ) ( Stage D exclude ) . ChildPugh stage A ( see Appendix 8 ) . Male female age 18 year old . Adequate haematological parameter , demonstrate : Haemoglobin great equal 9.0 g/dL ( SI unit : 5.6 mmol/L ) ; WBC great equal 3.0 x 109/L ; Platelets great equal 75 x 109/L . ALT AST ≤ 5 time upper limit normal . Bilirubin &lt; 2 mg/dL . Serum creatinine small equal 1.5 mg/dL ( SI unit : 132 µmol/L ) . Performance status ECOG 0 1 . Minimum life expectancy 3 month screen . Written informed consent give prior study specific procedure . HCC amenable curative treatment transplantation . History malignancy last 5 year ( 10 year case breast cancer ) , except adequately treat nonmelanoma skin cancer ( Basal Cell Carcinoma , Squamous Cell Carcinoma ) carcinoma situ cervix . Known history coexist autoimmune disease . Known Central Nervous System ( CNS ) metastases . Known history human immunodeficiency virus ( HIV ) . Any medical condition , opinion Investigator , may compromise compliance patient receive study treatment follow study procedure . Treatment IMP within 4 week prior cyclophosphamide administration Day 3 . Known sensitivity component cyclophosphamide , GV1001 GMCSF . Concomitant treatment follow within 4 week pretreatment cyclophosphamide : Antitumour treatment ( include radiotherapy , chemotherapy , immunotherapy , endocrine therapy , cytokine , interferon , protease inhibitor , gene therapy ) vaccine . Chronic corticosteroid ( inhaled topical steroid permit include low dose steroid nonimmunosuppressive dos e.g . 15 mg prednisolone daily 7 day ) . Herbal medicine either contain hypericum perforacum ( e.g. , St Johns Wort ) claim antitumour effect ( e.g. , Iscador ) . Pregnancy lactation . Women childbearing potential use reliable adequate contraceptive method , define use oral , implanted , injectable , mechanical barrier product prevention pregnancy ; woman practise abstinence ; partner sterile , example vasectomy . Unable reason comply protocol ( treatment assessment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Advanced Carcinoma , Hepatocellular</keyword>
</DOC>